Based on our August 2009 report, Hospital Anti-Infectives Insight Series: Clostridium Difficile, Arlington Medical Resources (AMR) and Decision Resources are offering an exclusive, in-depth webinar entitled Is Clostridium Difficile the New MRSA? Opportunities for Antibiotic Drug Development. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.
Please contact us to learn how you can purchase this report and attend the webinar.
Clostridium difficile is a gram-positive bacterium that can cause symptoms ranging from severe diarrhea to life-threatening inflammation of the colon. A new hypervirulent strain, BI/NAP1/027, has been associated with severe outbreaks of Clostridium difficile in North America and Europe, and has raised awareness about the need for improved treatment and prevention strategies for this infection.
Surveyed infectious disease specialists indicate that relapse or recurrence of infections and the lack of effective second- and later-line therapies are the most challenging aspects of treating Clostridium difficile infections in the hospital setting.
Presented by Decision Resources’ Analyst Lisa Arias this webinar will answer the following questions:
- What are the greatest unmet needs in the treatment of Clostridium difficile infections according to surveyed physicians?
- What attributes do physicians consider the most important in a new therapy to target Clostridium difficile?
- What are the key trends that surveyed infectious disease specialists expect to occur in the future?
- What does the pipeline for Clostridium difficile infections look like, and what are the remaining areas of opportunity for antibiotic developers?
Registration
Is Clostridium Difficile the New MRSA?
Opportunities for Antibiotic Drug Development
September 29, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To learn how you can purchase this Hospital Anti-Infectives Insight Series report and attend the webinar, please contact us using the information below.
Contact Us
For pricing information please contact any of the indivuals listed below.
In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com
In Europe — Inge Cornelis at +32-2-357-0619 or icornelis@decisionresources.be
In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp
|
|
|
Webinar Details
Date & Time
Tuesday, September 29, 2009
10:00 a.m. ET, 4:00 p.m. CET
|
|
Presentation: 30 minutes
Q & A: 15 minutes |
|
|
|
About the Speaker
Lisa Arias
Lisa Arias is an analyst in the infectious diseases group at Decision Resources. Prior to joining the company, she worked at the VA San Diego Medical Center on projects involving induction of antimicrobial peptides in skin and intestinal cells. She also worked in the Molecular Microbiology and Immunology Department at Brown University on cell signaling in response to bacterial DNA in immune cells. Ms. Arias graduated from Brown University with a B.A. in biology.
| |
